ZIM Laboratories Limited has made a strategic investment of Rs. 89.45 lakhs in its Australian subsidiary ZIMTAS Pty Ltd, as disclosed in a regulatory filing dated April 9, 2026. The investment represents a significant step in the company's international expansion strategy.

Investment Details

The pharmaceutical company has invested Rs. 89,45,100 (equivalent to AUD 1,35,000) in the equity shares of ZIMTAS Pty Ltd. This investment falls within the previously approved investment ceiling of up to Rs. 2.00 crores for the Australian subsidiary.

Shareholding Structure

Following this equity investment, ZIM Laboratories now holds 99.96% of the total share capital of ZIMTAS Pty Ltd, establishing near-complete ownership and control over the Australian entity. This substantial shareholding position strengthens the company's presence in the Australian market.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced previous intimations dated May 13, 2024, and July 2, 2024, indicating this investment was part of a planned strategic initiative.

Company Background

ZIM Laboratories Limited, operating under the motto "Zeal & Innovation in Medicine," continues to expand its international footprint through strategic investments. The company is listed on both BSE (Company Code: 541400) and NSE (Symbol: ZIMLAB), ensuring transparency in its corporate communications and regulatory disclosures.

ZIM Laboratories Limited has announced the appointment of Grant Thornton Bharat LLP as its internal auditor for a three-year term, marking a significant step in strengthening the company's governance framework. The appointment was approved during a board meeting held on March 30, 2026, following recommendations from the company's Audit Committee.

Board Meeting Details

The board meeting convened at 02:00 p.m. (IST) and concluded at 04:10 p.m. (IST) on March 30, 2026. The primary agenda focused on the appointment of the internal auditor in compliance with regulatory requirements.

Appointment Details

Grant Thornton Bharat LLP has been appointed as the internal auditor for a period of 3 years commencing from F.Y. 2026-27 to F.Y. 2028-29. The appointment aligns with Section 138 of the Companies Act, 2013, and follows the recommendations of the company's Audit Committee.

About Grant Thornton Bharat LLP

Grant Thornton Bharat LLP is a member of Grant Thornton International Ltd and operates as a leading professional services firm in India. The firm positions itself as a truly Indian firm with global connections, working with businesses and government across industries and sectors.

Regulatory Compliance

The appointment has been made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The company has provided all required disclosures as mandated by the regulatory framework.

The appointment reflects ZIM Laboratories' commitment to maintaining robust internal audit mechanisms and ensuring compliance with corporate governance standards. The three-year term provides continuity and allows for comprehensive internal audit coverage across the organization's operations.